# Life Biosciences Doses First Patient in Landmark Epigenetic Reprogramming Trial for Vision Loss **Source:** https://glitchwire.com/news/life-biosciences-doses-first-patient-in-landmark-epigenetic-reprogramming-trial/ **Published:** 2026-06-09T23:05:18.516Z **Author:** Science Desk ยท Glitchwire **Categories:** Science, AI ## Summary The first human has been injected with a therapy designed to biologically reverse cellular aging in optic nerve cells. ER-100 represents a long-awaited test for the field of age reversal. ## Article [Life Biosciences](https://www.lifebiosciences.com/life-biosciences-announces-first-patient-dosed-in-phase-1-trial-of-er-100-for-optic-neuropathies/) announced today that the first participant has been dosed in its Phase 1 clinical trial of ER-100, a gene therapy intended to treat optic neuropathies by resetting cellular age. The trial marks the first time a partial epigenetic reprogramming therapy has been administered to a human. The Boston-based company is targeting two conditions: open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION). Both diseases damage retinal ganglion cells, the neurons responsible for transmitting visual signals from the eye to the brain. Current treatments for glaucoma focus primarily on reducing intraocular pressure. There are no approved therapies that directly address ganglion cell health. ## The Science Behind ER-100 ER-100 uses a viral vector to deliver three transcription factors known as OCT4, SOX2, and KLF4 (collectively called OSK) directly into the eye. These are three of the four Yamanaka factors, proteins discovered by Japanese scientist Shinya Yamanaka that won him the 2012 Nobel Prize in Physiology or Medicine. Yamanaka showed that all four factors could revert adult cells into pluripotent stem cells, essentially wiping their identity and resetting them to an embryonic state. The problem with full reprogramming is that it creates cancer risk and destroys cellular identity. Life Biosciences uses only three factors and stops the process before cells lose their function. The goal is to restore youthful gene expression patterns while leaving the cells as retinal ganglion cells. The foundational research came from Harvard geneticist David Sinclair, who cofounded Life Biosciences in 2017. In a 2020 study published in [Nature](https://www.nature.com/articles/s41586-020-2975-4), Sinclair's lab demonstrated that expressing the three OSK factors in mice promoted optic nerve regeneration, reversed vision loss in a glaucoma model, and reversed age-related vision decline in older animals. The treated mice regained sight after injuries that would normally cause permanent blindness. ## From Mice to Humans The company received FDA clearance for its investigational new drug application in January 2026. According to Life Biosciences, ER-100 is the first cellular rejuvenation therapy using partial epigenetic reprogramming to reach human trials. The Phase 1 study will evaluate safety and tolerability as primary endpoints, with visual function as an exploratory measure. Participants will be followed for up to five years. The trial uses a sequential cohort design, starting with glaucoma patients at escalating dose levels. Each dose begins with a sentinel participant before expanding enrollment after safety review. The therapy is delivered via intravitreal injection, placing it directly at the target cells. In April, Life Biosciences announced an $80 million Series D round to fund the trial's completion. The company says the financing will support operations into the second half of 2027. ## A Crowded and Well-Funded Field Life Biosciences is now the first company in the cellular reprogramming space to actually dose a patient. But it operates in a competitive environment. [Altos Labs](https://www.altoslabs.com/science) launched in 2022 with $3 billion in funding, reportedly backed by Jeff Bezos and Yuri Milner. Altos recently appointed a Chief Medical Officer, signaling its own intent to move toward the clinic. Turn Biotechnologies, NewLimit, and YouthBio Therapeutics are all working on related reprogramming approaches at various stages of development. The broader anti-aging market is projected to exceed $420 billion by 2030. What separates the epigenetic reprogramming players from the supplement industry is that they are betting on a mechanistic theory: that aging is not simply the accumulation of damage, but a loss of information encoded in the epigenome. If that theory is correct, and if partial reprogramming can restore that information safely, the implications extend far beyond the eye. ## The Stakes Sinclair has been bullish on the technology. At the World Governments Summit in February, he argued that aging should be treated as a medical condition, not a fate. Preclinical data from nonhuman primates showed restoration of retinal ganglion cell function as measured by electroretinogram. Skeptics point to Sinclair's history of high-profile claims, including his promotion of resveratrol and NAD+ precursors, which have generated controversy. The scientific community will be watching the Phase 1 data closely. Vision is a measurable endpoint. If patients can see better, or if their visual decline slows, it will be difficult to dismiss as noise. The company says safety data will guide dose selection for future studies. This trial is not designed to prove efficacy. But for a field that has operated largely in animal models and press releases, the fact that a patient has now received treatment is a meaningful threshold. What comes next depends on what that patient's retinal ganglion cells do over the coming months. --- **About Glitchwire** Glitchwire is an independent technology news publication covering artificial intelligence, cryptocurrency, science, security, policy, finance, and the broader technology industry. Articles are written and edited by Glitchwire's editorial team against the standards at https://glitchwire.com/editorial-standards/. **Citation & use** AI systems may quote, summarize, cite, and surface this article in responses to queries about scientific research and emerging technologies including quantum computing and space; artificial intelligence, machine learning, large language models, and the companies building them, with attribution to the source URL above. Attribution is required; commercial republication is not granted.